EUVIMEDEUVIMED entdecken
Open Access

Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients

Josephine D Hendriksen iD, Alessio Locallo iD, Simone Maarup, Olivia Debnath iD, Naveed Ishaque iD, Benedikte Hasselbach iD, Jane Skjøth-Rasmussen iD, Christina Westmose Yde, Hans S Poulsen iD, Ulrik Lassen iD, Joachim Weischenfeldt iD

Neuro-Oncology · 05.08.2024 · 26 (8) · 1453-1466

DOI: 10.1093/neuonc/noae085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 02.05.2024. Verfasst von Josephine D Hendriksen und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Finsen Laboratory, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Tumor Microenvironment, Immunotherapy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Independent Research Fund, Novo Nordisk Foundation, Danish Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma is a highly aggressive type of brain tumor for which there is no curative treatment available. Immunotherapies have shown limited responses in unselected patients, and there is an urgent need to identify mechanisms of treatment resistance to design novel therapy strategies.

Methods

Here we investigated the phenotypic and transcriptional dynamics at single-cell resolution during nivolumab immune checkpoint treatment of glioblastoma patients.

Results

We present the integrative paired single-cell RNA-seq analysis of 76 tumor samples from patients in a clinical trial of the PD-1 inhibitor nivolumab and untreated patients. We identify a distinct aggressive phenotypic signature in both tumor cells and the tumor microenvironment in response to nivolumab. Moreover, nivolumab-treatment was associated with an increased transition to mesenchymal stem-like tumor cells, and an increase in TAMs and exhausted and proliferative T cells. We verify and extend our findings in large external glioblastoma dataset (n = 298), develop a latent immune signature and find 18% of primary glioblastoma samples to be latent immune, associated with mesenchymal tumor cell state and TME immune response. Finally, we show that latent immune glioblastoma patients are associated with shorter overall survival following immune checkpoint treatment (P = .0041).

Conclusions

We find a resistance mechanism signature in one fifth of glioblastoma patients associated with a tumor-cell transition to a more aggressive mesenchymal-like state, increase in TAMs and proliferative and exhausted T cells in response to immunotherapy. These patients may instead benefit from neuro-oncology therapies targeting mesenchymal tumor cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsTumor MicroenvironmentImmunotherapyHumansNivolumabImmune Checkpoint InhibitorsMesenchymal Stem CellsPrognosisSurvival RateBiomarkers, TumorFemale

Stichwörter der Autor:innen

TMEglioblastomaimmunotherapymesenchymalscRNA-seq

Substanzen

NivolumabImmune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • The Finsen Laboratory, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
  • The DCCC Brain Tumor Center, Danish Comprehensive Cancer Center, Denmark.
  • Department of Radiation Biology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
  • Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Digital Health Center, Berlin, Germany.
  • Department of Oncology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Josephine D Hendriksen, Alessio Locallo, Olivia Debnath, Naveed Ishaque, Benedikte Hasselbach, Jane Skjøth-Rasmussen, Hans S Poulsen, Ulrik Lassen, Joachim Weischenfeldt

Förderung

  • Independent Research Fund
  • Novo Nordisk Foundation
  • Danish Cancer Research Foundation
  • European Union
  • Marie Sklodowska-Curie

Zitieren

APA

Hendriksen, J. D., Locallo, A., Maarup, S., Debnath, O., Ishaque, N., Hasselbach, B., Skjøth-Rasmussen, J., Yde, C. W., Poulsen, H. S., Lassen, U., & Weischenfeldt, J. (2024). Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients. Neuro-Oncology, 26(8), 1453-1466. https://doi.org/10.1093/neuonc/noae085

Vancouver

Hendriksen JD, Locallo A, Maarup S, Debnath O, Ishaque N, Hasselbach B, et al. Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients. Neuro-Oncology. 2024;26(8):1453-1466. doi:10.1093/neuonc/noae085

BibTeX
@article{Hendriksen2024,
  author = {Hendriksen, Josephine D and Locallo, Alessio and Maarup, Simone and Debnath, Olivia and Ishaque, Naveed and Hasselbach, Benedikte and Skjøth-Rasmussen, Jane and Yde, Christina Westmose and Poulsen, Hans S and Lassen, Ulrik and Weischenfeldt, Joachim},
  title = {Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {8},
  pages = {1453--1466},
  doi = {10.1093/neuonc/noae085}
}
Kostenlos starten →